纳地美定止痛效果怎么样?

Author: Medicalhalo

Release time: 2025-10-19 11:44:20

Nadimedine has a good analgesic effect and ultimately improves the quality of life of cancer patients by improving the analgesic experience of cancer pain patients using opioids. Nadimedine tablets are antagonists that act on μ-opioid receptors in the peripheral nervous system, referred to as PAMORAs, developed by Shionogi Pharmaceutical Co., Ltd., and are used to treat non-cancer pain and opioid-induced constipation. It can fundamentally treat constipation in patients with OIC (opioid-associated constipation) by antagonizing the physiological effects of opioids on the enteric nervous system in peripheral tissues (especially the enteric nervous system), regulating intestinal peristalsis and secretory activities.

Nadimedine test results

This study evaluates the efficacy and safety of peripherally acting μ-opioid receptor antagonists in the treatment of opioid-induced constipation in patients with chronic noncancer pain.

Test method

reported on two double-blind, randomized, placebo-controlled trials (NCT01965158 and NCT01993940) in adults with chronic noncancer pain and opioid-induced constipation.

Eligible patients were aged 18–80 years, not using laxatives, and had a stable opioid regimen for chronic non-cancer pain for at least 1 month before screening, with a total daily average of at least 30 mg (morphine equivalents). Patients were randomly assigned (1:1) to receive oral naldimedine 0-2 mg or the same placebo once daily for 12 weeks. Random assignment was stratified by mean total daily opioid dose (30-100 mg and >100 mg equivalents of oral morphine sulfate).

The primary endpoint was the proportion of responders. Responders were defined as having at least three spontaneous bowel movements (SBM) per week for at least 9 weeks of the 12-week treatment period (including at least 3 of the last 4 weeks) and at least one additional SBM per week compared with baseline.

Research results

In both COMPOSE-1 and COMPOSE-2 trials, the proportion of responders to naldimedine was significantly higher than that of placebo (130 of 273 patients in the naldimedine group [47-6%] responded, and 94 of 272 patients in the placebo group [34-6%] responded, a difference of 13-0% [95% CI] 4-8-21-3]; P=0-002) (145 of 276 patients in the COMPOSE-2 group [52-5%] were responders, and 92 of 274 patients in the placebo group were responders [33-6%], the difference was 18-9% [10-8-27-0]; P<0-0001).

Test conclusion

Naldimedine treatment can make patients lose weight. The response rate of naldimedine treatment is significantly higher than that of placebo, and it is generally well tolerated. These results support naldimedine as a new option for the treatment of opioid-induced constipation in patients with chronic non-cancer pain.

Drug purchasing channels for Nadimedin

Nadimedine has not been launched in mainland China as of October 11, 2023. Currently, this product is not available in hospital pharmacies in the country. Currently, there are two main channels for Nadimeding:

1. Go to areas where the drug is already on the market, but you need to go to the local regular hospital pharmacy to buy it. Do not be greedy for cheap and ensure the quality and source of the drug.

2. Patients who are inconvenient to travel far can purchase it online and get it with the help of domestic professional overseas medical service organizations (such as Medical Companion Travel). The medicine can be mailed to their home, guaranteed to be genuine, saving them the trouble of traveling to buy medicine and reducing a considerable financial burden. However, the price is subject to various factors and is not fixed. It is recommended to consult customer service staff for specific costs and acquisition procedures. Obtaining medicines is guaranteed.

Menu